MANA Therapeutics Appoints Arthur Hurwitz as Chief Scientific Officer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
New drug class effective in treating certain types of ovarian cancers
A study published today in Nature Communications shows that the drug rucaparib has been effective in treating certain types of ovarian cancers if used early in treatment, after a diagnosis, and before the cancer cells build up a resistance to chemotherapy.
Rucaparib is in a relatively new class of drugs - Poly(ADP-ribose) polymerase or PARP inhibitors - which have been approved for therapy in ovarian cancers. This study provides insights into both how the cancers resist treatments, and which patients may respond favorably to the drug, said lead author Dr. Elizabeth Swisher, a UW Medicine gynecologic oncologist and a professor of obstetrics and gynecology at the University of Washington School of Medicine. She also co-directs the Breast and Ovarian Cancer Research Program at the Seattle Cancer Care Alliance.
New class of drug gives hope to some ovarian cancer patients newswise.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswise.com Daily Mail and Mail on Sunday newspapers.
With COVID-19 vaccine in short supply, confusion abounds over second shots By Sandi Doughton, The Seattle Times
Published: February 5, 2021, 10:30am
Share:
At 71 years old, Lisa Soli was delighted to snag a coveted COVID-19 vaccine during a clinic last month at Overlake Medical Center in Bellevue. But when the retired educator asked about her second dose, the nurse told her they weren’t scheduling boosters and wished her luck finding one.
Soli has been searching ever since.
“You just have to get lucky, and it shouldn’t be that way,” she said. “This is critical life-and-death stuff for those of us over 65.”